BeiGene, Ltd. (BGNE) Financials
Stock symbol BGNE is outdated, potentially delisted? Maybe it is available on other exchange?
BGNE Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| Sept. 30, 2024 | 5.8 billion | 2.4 billion |
| June 30, 2024 | 5.7 billion | 2.3 billion |
| March 31, 2024 | 5.7 billion | 2.3 billion |
| Dec. 31, 2023 | 5.8 billion | 2.3 billion |
BGNE Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| Sept. 30, 2024 | 54.7 million | 114.7 million |
| June 30, 2024 | -205.5 million | 130.6 million |
| March 31, 2024 | -501.6 million | 88.7 million |
| Dec. 31, 2023 | -388.5 million | 92.8 million |
BGNE Net Income
No data available :(
BGNE Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| Sept. 30, 2024 | 2.7 billion | 220.0 million | 50.2 million |
| June 30, 2024 | 2.6 billion | 220.7 million | 53.1 million |
| March 31, 2024 | 2.8 billion | 216.7 million | 37.1 million |
| Dec. 31, 2023 | 3.2 billion | 219.9 million | 44.2 million |
BGNE Shares Outstanding
BGNE Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| Sept. 30, 2024 | 133.7 million | 496.2 million | 455.2 million | - |
| June 30, 2024 | 110.0 million | 454.5 million | 443.7 million | - |
| March 31, 2024 | 193.1 million | 460.6 million | 427.4 million | - |
| Dec. 31, 2023 | 166.9 million | 494.0 million | 416.5 million | - |
BGNE Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| Sept. 30, 2024 | 1.0 billion | 170.5 million |
| June 30, 2024 | 929.2 million | 138.1 million |
| March 31, 2024 | 751.7 million | 124.9 million |
| Dec. 31, 2023 | 634.4 million | 105.8 million |
BGNE Revenue by Segment
Graph available only for paid members. Upgrade to see it.
BGNE
Price: $184.71
52 week price:
Earnings Per Share: -8.19 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: Cayman Islands
Volume: 346500
Ebitda: 116.2 millionMarket Capitalization: 20.2 billion